Aegis Sciences Corporation is proud to celebrate 35 years of laboratory innovation and public health impact. Aegis delivers clinical insights to support healthcare providers, public health officials, and researchers across the country. Our work enables risk reduction and effective clinical decisions in pain management, behavioral health, infectious disease surveillance and, above all, the fight against the opioid crisis.
Providing Clinicians with Clarity
Aegis delivers Clarity through comprehensive drug testing solutions that offer a more objective measure of prescription and non-prescription substances used by individuals receiving care for a variety of conditions. Definitive testing for the right substances in oral fluid or urine provides information that can save lives.
Who We Serve
Whether you are a pain management provider looking to optimize treatment plans or a behavioral health provider looking for an objective tool to overcome medication adherence barriers, our products are uniquely designed for appropriate intervention to improve patient care.
Pain Management
Aegis PainComp® was designed to assure the most complete care for individuals receiving treatment for chronic pain. Testing for adherence with prescribed medications provides assurance for clinicians that patients are only taking the ordered medications and are not using non-prescribed or illicit drugs that could cause harm.
Mental Illness
Aegis AcuRise IDTM was designed to help clinicians identify and overcome adherence barriers in the treatment of mental illness. Testing can be used as an objective measure of adherence. It can also allow assessment of commonly used non-prescription substances which may impact the individual’s symptoms. AcuRise ID testing provides answers to aid in the enhanced care of people living with mental illness.
Substance Use Disorder
Aegis AcuRiseIDTM adherence testing assists in the continuous monitoring of a person’s recovery and helps build trust between a prescriber and individuals in their care regarding treatment adherence and progress towards goals. Testing can be used to detect inappropriate prescription drug or substance use, whether intentional or unintentional, and diversion of prescription medications.
Aegis AcuRiseID allows for monitoring progress toward treatment goals and helps prevent human tragedy for those living with substance use disorder.
Sports Testing
Aegis is the largest independent anti-doping laboratory in the U.S. operating out of the Wilma Rudolph Sports Testing Laboratory and serving more than 150 top U.S. colleges, universities, high schools, and professional sports organizations. Through our Zero-Tolerance® drug testing services, Aegis offers testing for a variety of performance enhancing substances including: anabolic steroids, stimulants (including ephedrine), diuretics, and beta blockers.
Aegis Launches Innovative Dashboard to Track Novel Psychoactive Substances
This industry-leading tool offers a unique real-time visual representation of definitive testing results from the millions of specimens analyzed by Aegis to provide real-time insights into the presence of NPS across the United States. This tool enables policymakers, public health officials, and clinicians to make informed decisions in response to the synthetic drug crisis.
Testimonials
Aegis has truly been eye-opening in identifying usage of designer drugs, which seem to be rising in usage over the past years and are not identified through other drug testing platforms. This allows us to further assess each patient’s adherence to treatment and avoid dangerous interactions that can come from prescribing specific medications to patients who are using designer drugs illicitly.
Halie L. Ory, MPAS, PA-C, Psychiatry CAQ
Resource Management Services
You don’t know what you don’t know. The standard ‘run of the mill’ drug testing in general leaves out so much. Working with panels that are up-to date allows for knowledge of what is in my area now.
Dr. Sarah Calnan
Board-Certified Psychiatrist &
Board-Certified Addiction Medicine
The individual in my care was completely unaware that she had received a drug that was substituted with a designer benzodiazepine. This opened the door for a greater understanding of the risks of her substance use, and eventually led to her seeking out rehabilitative care. Having the ability to identify at-risk compounds helps to keep those I care for safe, and in this case, led to a significantly improved clinical outcome for this individual.
Kate Mariani, Physician Assistant
Family Medicine Specialists
